Suppr超能文献

[幽门螺杆菌菌株对抗菌药物耐药性的当前观点]

[Current perspective of the resistance of Helicobacter pylori strains to antimicrobial drugs].

作者信息

Lochmannová Jindra

机构信息

Department of Internal Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.

出版信息

Klin Mikrobiol Infekc Lek. 2010 Dec;16(6):199-202.

Abstract

A significant increase in H. pylori resistance to clarithromycin and metronidazole has been proven in both children and adults. Clarithromycin with resistance over 20 % and metronidazole with resistance over 40 % are not recommended for treating H. pylori infection. Preferred treatment regimens were designed to reflect the current situation. The classical regimen PPI + AMO + CLA (MET) can be used in cases where the resistance against CLA and MET is lower than stated above. In the opposite case, a combination of PPI + AMO + levofloxacin (or rifabutin, or furazolidone) must be used. In many countries, this regimen is already the first-choice treatment. The 4-combination with bismuth is suitable in case of 3-combination treatment failure, or in patients allergic to penicillin.

摘要

已证实儿童和成人中幽门螺杆菌对克拉霉素和甲硝唑的耐药性均显著增加。克拉霉素耐药率超过20%以及甲硝唑耐药率超过40%的情况不建议用于治疗幽门螺杆菌感染。设计了首选治疗方案以反映当前情况。经典方案PPI + AMO + CLA(MET)可用于对CLA和MET的耐药性低于上述情况的病例。反之,则必须使用PPI + AMO +左氧氟沙星(或利福布汀,或呋喃唑酮)的联合方案。在许多国家,该方案已是首选治疗方法。三联疗法失败或对青霉素过敏的患者适用含铋剂的四联疗法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验